Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Arch Therapeutics Inc

Healthcare US ARTH

NoneUSD
0.00(0%)

Last update at 2025-08-04T13:01:39.051143Z

Day Range

--
LowHigh

52 Week Range

0.179.00
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap0.84M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.71957M
  • Revenue TTM0.15M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -0.03584M
  • Diluted EPS TTM-1.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -5.27585M -6.24048M -4.69138M -4.54758M -4.81403M
Minority interest - - - - -
Net income -5.27585M -6.24048M -4.69138M -4.54758M -4.81403M
Selling general administrative 4.52M 5.01M 3.76M 3.97M 4.57M
Selling and marketing expenses - - - - -
Gross profit -0.03584M -0.01472M - - 0.00000M
Reconciled depreciation 0.00320M 0.00259M 0.00693M 0.00824M 0.00534M
Ebit -5.70881M -6.37712M -4.69138M -6.37176M -7.44977M
Ebitda -4.70561M -6.08736M -5.36372M -6.36352M -4.80869M
Depreciation and amortization - - - - -
Non operating income net other - - 0.68M - 2.64M
Operating income -5.70881M -6.37712M -5.37065M -6.37176M -7.44977M
Other operating expenses - - - - -
Interest expense 0.57M 0.15M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.56705M -0.15053M - - 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 0.02M 0.01M 0.00000M 0.00000M 0.00000M
Total operating expenses 5.72M 6.39M 5.37M 6.37M 7.45M
Cost of revenue 0.05M 0.03M - - 0.00000M
Total other income expense net 1.00M 0.29M 0.68M 1.82M 2.64M
Discontinued operations - - - - -
Net income from continuing ops -5.27585M -6.24048M -4.69138M -4.54758M -4.81403M
Net income applicable to common shares -5.27585M -6.24048M -4.69138M -4.54758M -4.81403M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 1.96M 2.60M 3.68M 2.15M 2.90M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.36M - - 0.22M -
Total liab 9.47M 6.80M 4.70M 3.65M 3.71M
Total stockholder equity -7.50773M -4.19280M -1.02567M -1.50049M -0.80730M
Deferred long term liab - - - 2.32M -
Other current liab 0.24M 0.75M 1.00M - -
Common stock - 0.25M 0.24M 0.19M 0.17M
Capital stock 0.00469M 0.25M 0.24M 0.19M 0.17M
Retained earnings -62.05561M -55.07277M -49.79692M -43.55644M -38.86506M
Other liab - 0.66M 1.37M 2.32M 3.00M
Good will - - - - -
Other assets - 0.00350M 0.00350M 0.00350M 0.00350M
Cash 0.22M 0.75M 2.27M 0.96M 2.18M
Cash and equivalents - - - - -
Total current liabilities 9.47M 3.32M 1.73M 0.65M 0.71M
Current deferred revenue - - - - -
Net debt 5.41M 2.62M 0.33M - -
Short term debt - - - 0.04M -
Short long term debt 5.63M 0.55M 1.00M 0.04M -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - 0.00204M 0.00524M 0.00455M 0.00902M
Total current assets 1.95M 2.60M 3.67M 2.14M 2.89M
Long term investments - - - - -
Net tangible assets - -4.19280M -1.02567M -1.50049M -0.80730M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - 2.81M 1.60M 0.14M -
Inventory 1.36M 1.41M 1.09M 0.97M 0.35M
Accounts payable 2.30M 1.33M 0.41M 0.61M 0.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.19M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -43.55644M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00350M 0.00350M 0.00350M 0.00350M 0.00350M
Deferred long term asset charges - - - - -
Non current assets total 0.00810M 0.00554M 0.00874M 0.00805M 0.01M
Capital lease obligations - - - - -
Long term debt total - - - 0.14M -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments 0.00000M -0.00328M -0.00246M 0.00000M -0.01541M
Change to liabilities 0.85M 0.07M -0.10501M 0.37M -0.10393M
Total cashflows from investing activities - -0.00328M -0.00246M -0.00246M -0.01541M
Net borrowings 3.42M 1.05M 0.73M 0.73M 0.73M
Total cash from financing activities 2.94M 7.27M 3.83M 2.78M 4.60M
Change to operating activities 0.49M 0.13M 0.23M -0.15809M -0.10767M
Net income -5.27585M -6.24048M -4.69138M -4.54758M -4.81403M
Change in cash -1.51970M 1.31M -1.22102M -2.48708M -1.32664M
Begin period cash flow 2.27M 0.96M 2.18M 4.67M 5.99M
End period cash flow 0.75M 2.27M 0.96M 2.18M 4.67M
Total cash from operating activities -4.45608M -5.95863M -5.04476M -5.26830M -5.91356M
Issuance of capital stock 0.00000M 6.22M 2.17M 2.75M 4.46M
Depreciation 0.00320M 0.00259M 0.00693M 0.00824M 0.00534M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.56916M -0.30776M -0.68173M -0.34665M -0.34665M
Change to account receivables - - - - -
Sale purchase of stock - - 0.93M - 4.60M
Other cashflows from financing activities -0.48237M -0.48237M 2.17M 1.63M 2.40M
Change to netincome 0.05M 0.39M 0.28M -0.59683M -0.89328M
Capital expenditures 0.00000M 0.00328M 0.00246M 0.00246M 0.02M
Change receivables - - - - -
Cash flows other operating - - 0.15M - -0.06645M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -1.22102M - -1.32664M
Change in working capital 0.77M -0.11161M -0.63971M -0.13213M -0.21160M
Stock based compensation 0.50M 0.50M 0.90M 1.18M -
Other non cash items 0.30M - - 0.04M -
Free cash flow -4.45608M -5.96190M -5.04721M -5.26830M -5.92898M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARTH
Arch Therapeutics Inc		 - -% - - 0.08 5.70 34.61 69.16 -3.4359
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Arch Therapeutics Inc

235 Walnut Street, Framingham, MA, United States, 01702

Key Executives

Name Title Year Born
Dr. Terrence W. Norchi M.D. Co-Founder, Chairman, Pres & CEO 1965
Mr. Michael S. Abrams Chief Financial Officer 1970
Mr. Daniel M. Yrigoyen VP of Sales 1970
Dr. Rutledge Ellis-Behnke Ph.D. Co-Founder & Scientific Advisor NA
Dr. Steven A. Kates Ph.D. VP of Technology NA
Mr. Daniel C. Wadsworth Jr. Advisor & Consultant of Wound Care Commercialization 1954
Dr. Terrence W. Norchi M.D. Co-Founder, Chairman, President & CEO 1965
Mr. Michael S. Abrams CFO & Treasurer 1970
Mr. Shawn Carlson Vice President of Sales NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions